These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24336903)

  • 1. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
    Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
    Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption.
    Shugg RP; Thomson A; Tanabe N; Kashishian A; Steiner BH; Puri KD; Pereverzev A; Lannutti BJ; Jirik FR; Dixon SJ; Sims SM
    J Biol Chem; 2013 Dec; 288(49):35346-57. PubMed ID: 24133210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of PI3Kβ-selective inhibition revealed by reciprocal mutagenesis.
    Zheng Z; Miller MS; Jennings IG; Thompson PE
    ACS Chem Biol; 2013 Apr; 8(4):679-83. PubMed ID: 23360067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Determinants of Isoform Selectivity in PI3K Inhibitors.
    Miller MS; Thompson PE; Gabelli SB
    Biomolecules; 2019 Feb; 9(3):. PubMed ID: 30813656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) β Inhibitor.
    Chandrasekhar J; Dick R; Van Veldhuizen J; Koditek D; Lepist EI; McGrath ME; Patel L; Phillips G; Sedillo K; Somoza JR; Therrien J; Till NA; Treiberg J; Villaseñor AG; Zherebina Y; Perreault S
    J Med Chem; 2018 Aug; 61(15):6858-6868. PubMed ID: 30015489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.
    Sabbah DA; Vennerstrom JL; Zhong HA
    J Chem Inf Model; 2012 Dec; 52(12):3213-24. PubMed ID: 23157418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.
    Heffron TP; Wei B; Olivero A; Staben ST; Tsui V; Do S; Dotson J; Folkes AJ; Goldsmith P; Goldsmith R; Gunzner J; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Shuttleworth S; Sutherlin DP; Wan NC; Wang S; Wiesmann C; Zhu BY
    J Med Chem; 2011 Nov; 54(22):7815-33. PubMed ID: 21985639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα.
    Kim J; Hong S; Hong S
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6977-81. PubMed ID: 22030027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket.
    Frazzetto M; Suphioglu C; Zhu J; Schmidt-Kittler O; Jennings IG; Cranmer SL; Jackson SP; Kinzler KW; Vogelstein B; Thompson PE
    Biochem J; 2008 Sep; 414(3):383-90. PubMed ID: 18489260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
    Collier PN; Messersmith D; Le Tiran A; Bandarage UK; Boucher C; Come J; Cottrell KM; Damagnez V; Doran JD; Griffith JP; Khare-Pandit S; Krueger EB; Ledeboer MW; Ledford B; Liao Y; Mahajan S; Moody CS; Roday S; Wang T; Xu J; Aronov AM
    J Med Chem; 2015 Jul; 58(14):5684-8. PubMed ID: 26121481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
    Ameriks MK; Venable JD
    Curr Top Med Chem; 2009; 9(8):738-53. PubMed ID: 19689378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis.
    Bartok B; Boyle DL; Liu Y; Ren P; Ball ST; Bugbee WD; Rommel C; Firestein GS
    Am J Pathol; 2012 May; 180(5):1906-16. PubMed ID: 22433439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition.
    Zheng Z; Amran SI; Thompson PE; Jennings IG
    Mol Pharmacol; 2011 Oct; 80(4):657-64. PubMed ID: 21778304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.
    Staben ST; Ndubaku C; Blaquiere N; Belvin M; Bull RJ; Dudley D; Edgar K; Gray D; Heald R; Heffron TP; Jones GE; Jones M; Kolesnikov A; Lee L; Lesnick J; Lewis C; Murray J; McLean NJ; Nonomiya J; Olivero AG; Ord R; Pang J; Price S; Prior WW; Rouge L; Salphati L; Sampath D; Wallin J; Wang L; Wei B; Weismann C; Wu P
    Bioorg Med Chem Lett; 2013 May; 23(9):2606-13. PubMed ID: 23540645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
    Certal V; Halley F; Virone-Oddos A; Delorme C; Karlsson A; Rak A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Carry JC; Abecassis PY; Lejeune P; Vincent L; Bonnevaux H; Nicolas JP; Bertrand T; Marquette JP; Michot N; Benard T; Below P; Vade I; Chatreaux F; Lebourg G; Pilorge F; Angouillant-Boniface O; Louboutin A; Lengauer C; Schio L
    J Med Chem; 2012 May; 55(10):4788-805. PubMed ID: 22524426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential.
    Ghigo A; Hirsch E
    Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors.
    Yadav RR; Guru SK; Joshi P; Mahajan G; Mintoo MJ; Kumar V; Bharate SS; Mondhe DM; Vishwakarma RA; Bhushan S; Bharate SB
    Eur J Med Chem; 2016 Oct; 122():731-743. PubMed ID: 27479483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational study reveals substituted benzimidazole derivatives' binding selectivity to PI3Kδ and PI3Kγ.
    Zhang NN; Bai X; Zhao SS; Zheng XM; Tang L; Yang SG; Zhang JQ
    J Mol Model; 2022 Apr; 28(5):123. PubMed ID: 35438328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ.
    Miller MS; Mountford SJ; Pinson JA; Zheng Z; Künzli M; Patel V; Hogg SJ; Shortt J; Jennings IG; Thompson PE
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4790-4794. PubMed ID: 27561716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.